Inj vedolizumab iv 1 mg
Products billed under this code include Entyvio.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Entyvio.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Entyvio | Takeda Pharmaceuticals America, Inc. | 64764-0300-20 | 300 | $6,284.70 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $20.949 | −$0.673 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $21.622 | +$1.109 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $20.513 | −$0.858 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $21.371 | +$0.06 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $21.311 | −$0.751 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $22.062 | +$0.90 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $21.162 | −$0.508 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $21.67 | −$0.59 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $22.26 | −$0.617 | 1 MG | Inj vedolizumab iv 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $22.877 | +$1.024 | 1 MG | Injection, vedolizumab | v1, posted June 11, 2025 |
| 2Q24 | $21.853 | −$0.21 | 1 MG | Injection, vedolizumab | v1, posted March 11, 2025 |
| 1Q24 | $22.063 | −$0.233 | 1 MG | Injection, vedolizumab | v1, posted December 19, 2024 |
| 4Q23 | $22.296 | −$0.381 | 1 MG | Injection, vedolizumab | v1, posted October 10, 2024 |
| 3Q23 | $22.677 | +$0.837 | 1 MG | Injection, vedolizumab | v1, posted June 5, 2024 |
| 2Q23 | $21.84 | +$0.145 | 1 MG | Injection, vedolizumab | v1, posted February 23, 2024 |
| 1Q23 | $21.695 | −$0.602 | 1 MG | Injection, vedolizumab | v1, posted December 6, 2023 |
| 4Q22 | $22.297 | −$0.46 | 1 MG | Injection, vedolizumab | v1, posted June 22, 2023 |
| 3Q22 | $22.757 | +$1.037 | 1 MG | Injection, vedolizumab | v1, posted June 9, 2023 |
| 2Q22 | $21.72 | +$0.427 | 1 MG | Injection, vedolizumab | v1, posted December 14, 2022 |
| 1Q22 | $21.293 | +$0.014 | 1 MG | Injection, vedolizumab | v1, posted June 8, 2022 |
| 4Q21 | $21.279 | +$0.264 | 1 MG | Injection, vedolizumab | v1, posted June 2, 2022 |
| 3Q21 | $21.015 | +$0.349 | 1 MG | Injection, vedolizumab | v1, posted June 2, 2022 |
| 2Q21 | $20.666 | +$0.318 | 1 MG | Injection, vedolizumab | v1, posted March 1, 2022 |
| 1Q21 | $20.348 | – | 1 MG | Injection, vedolizumab | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.